We are committed to collaborating with our partners to develop the most innovative therapies to address unmet medical needs in the area of immunological diseases.
SinoMab has developed a pipeline of pre-clinical, clinical and pre-registration stage first-in-class assets addressing various inflammation & immunology diseases, such as rheumatoid arthritis, asthma, atopic dermatitis and Alzheimer’s disease.
Capitalizing on our in-house R&D capabilities, proven track record of successful development of innovative drug candidates, and our established manufacturing capabilities, we believe we are an attractive partner of choice for pharmaceutical companies and biotechnology companies.
To accelerate the development of our innovative drug candidates, we are open to collaboration, partnerships and licensing agreement with partners worldwide.
Our areas of focus for business development are:
- Autoimmune diseases
- Neuro-inflammatory diseases
Given our strong in-house research and development capabilities, we have established global collaboration relationships with reputable companies and scientific research institutions.
